Non-small Cell Lung Cancer (NSCLC) pipeline constitutes 135+ key companies continuously working towards developing 150+ NSCLC treatment therapies, analyzes DelveInsight
DelveInsight’s ‘Non-small Cell Lung Cancer Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-small cell lung cancer pipeline domain.
To know more about the NSCLC Market report offerings, click here: NSCLC Market Insight
Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report
- Over 150+ Non-small cell lung cancer pipeline therapies are in various stages of development, and their anticipated acceptance in the Non-small cell lung cancer market would significantly increase market revenue.
- Some of the Non-small cell lung cancer companies developing novel drug candidates to improve the NSCLC treatment landscape include BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
- Promising Non-small cell lung cancer therapies in various stages of development include INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
- In Oct 2022, eftilagimod alpha has been given a fast-track designation by the FDA for use as the first-line treatment for patients with stage IIIB/IV non-small cell lung cancer when combined with pembrolizumab.
- In Oct 2022, BerGenBio announced that they had begun the phase Ib/IIa trial evaluating bemcentinib in first-line non-small cell lung cancer patients with STK11 mutations.
- In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape in @ Non-small Cell Lung Cancer Pipeline Report
Non-small Cell Lung Cancer Overview
About 85% of all cases of lung cancer are non-small-cell lung cancer (NSCLC), which includes all epithelial lung cancers besides small-cell lung cancer (SCLC). NSCLC tumors come in three different varieties: a) Adenocarcinoma begins in cells that produce mucus and other substances inside air sacs, frequently in the outer regions of your lungs. It is the most prevalent form of lung cancer in people under 45 who smoke, nonsmokers, and both.
The common NSCLC symptoms include chest pain, wheezing, weight loss, shortness of breath, coughing up blood, and others. Several imaging tests such as X-ray, MRI, PET Scans, CT Scans, and others are used for NSCLC diagnosis. Apart from imaging tests, other tests used for NSCLC diagnosis include sputum cytology, bronchoscopy, and mediastinoscopy.
Non-small Cell Lung Cancer Pipeline Analysis: Drug Profile
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Datopotamab deruxtecan is one of three leading ADCs in Daiichi Sankyo’s oncology pipeline and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is made up of a humanized anti-TROP2 IgG13 monoclonal antibody developed in collaboration with Sapporo Medical University, which is linked to several topoisomerases I inhibitor payloads, an exatecan derivative via tetrapeptide-based cleavable linkers.
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized for long-term target inhibition, which may be important in treating KRASG12C-mutated cancers because the KRASG12C protein regenerates every 24-48 hours. Adagrasib is being tested in patients with advanced KRASG12C-mutated solid tumors, such as NSCLC, colorectal cancer, and pancreatic cancer, as a monotherapy and in combination with other anti-cancer therapies.
Non-small Cell Lung Cancer Therapies and Key Companies
- Datopotamab deruxtecan: Daiichi Sankyo
- JDQ443: Novartis
- MRTX849: Mirati Therapeutics
- INBRX-106: Inhibrx
- GB 1211: Galecto Biotech
- BBP 398: BridgeBio Pharma
- TGRX 326: Shenzhen TargetRx
- SRF388: Surface Oncology
- ABBV 514: AbbVie
Learn more about the NSCLC emerging pipeline therapies @Non-small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Intranasal
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Transdermal
- By Molecule Type
- Antisense oligonucleotide
- Gene therapy
- Hormones
- Neuropeptides
- Oligonucleotides
- Small Molecule
- Triglyceride
Scope of the Non-small Cell Lung Cancer Pipeline Report
- Coverage: Global
- Key Non-small Cell Lung Cancer Companies: BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo, EMD Serono (ETR: MRK), Merck (NYSE: MRK), Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer (ETR: BAYN), GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene (ASX: IMU), Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb (NYSE: BMY), Surface Oncology (NASDAQ: SURF), Inhibrx (NASDAQ: INBX), Sinocelltech, Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development, Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
- Key Non-small Cell Lung Cancer Pipeline Therapies: INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ Non-small Cell Lung Cancer Emerging Therapies
Table of Contents
|
1. |
Introduction |
|
2. |
Executive Summary |
|
3. |
Overview |
|
4. |
Non-small Cell Lung Cancer Pipeline Therapeutics |
|
5. |
Late Stage Non-small Cell Lung Cancer Products (Phase III) |
|
6. |
Mid Stage Non-small Cell Lung Cancer Products (Phase II) |
|
7. |
Early Stage Non-small Cell Lung Cancer Products (Phase I/II) |
|
8. |
Preclinical Stage Products |
|
9. |
Discovery Stage Products |
|
10. |
Non-small Cell Lung Cancer Therapeutic Assessment |
|
11. |
Inactive Non-small Cell Lung Cancer Products |
|
12. |
Collaborations Assessment- Licensing / Partnering / Funding |
|
13. |
Non-small Cell Lung Cancer Unmet Needs |
|
14. |
Non-small Cell Lung Cancer Market Drivers and Barriers |
|
15. |
Appendix |
|
16. |
About DelveInsight |
For further information on the NSCLC current pipeline therapeutics, reach out @ Non-small Cell Lung Cancer Therapeutics Assessment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting